7月15日，生物科技公司君实生物在科创板成功上市，此次上市募资额超过48亿元人民币。嘉源律师事务所担任发行人律师，天元律师事务所则为保荐人及主承销商中金公司提供法律意见。

2012年创立于上海，君实生物致力于创新药物的发现和开发，以及在全球范围内的临床研发及商业化。其目前核心产品为针对黑色素瘤的特瑞普利单抗注射液，此外还针对包括鼻咽癌、尿路上皮癌在内多种癌症进行研发，目前共有21项在研产品，其中 19个为创新药。

君实生物2018年12月在香港上市，是港交所18A章节生效后首批上市的未盈利生物科技企业之一。此次科创板成功上市，使其成为了“H股+科创板”未盈利生物科技第一股。此次募资将用于药物研发、支持新产业化项目等。

嘉源团队本项目牵头律师为高级合伙人王元、合伙人吴婧倩。

Jia Yuan, Tian Yuan on Junshi Biosciences’ $686 mln STAR Market IPO

Jia Yuan Law Offices has advised biotech company Junshi Biosciences on its $686 million initial public offering on the Shanghai STAR Market, with Tian Yuan Law firm advising the sole sponsor CICC.

Found in Shanghai in 2012, Junshi is an innovation-driven biopharmaceutical company with Toripalimab Injection, a medicine targeting at skin cancer, as its main product. It now has twenty-one products in its R&D pipeline and nineteen of them are innovative drugs.

Junshi was listed in Hong Kong back in 2018 and was one of the pioneer companies being listed under HKEX’s 18A chapter after it came into effect. The current IPO makes it the first pre-revenue biotech company to have a dual listing on both A and H shares.

The Jia Yuan team was led by senior partner Wang Yuan, with assistance from intellectual property partner Wu Jingqian.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.